TriSalus Life Sciences, Inc.
TLSI
$5.32
$0.254.93%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Net Income | 21.44% | 71.64% | -61.00% | 69.00% | -59.72% |
Total Depreciation and Amortization | -1.71% | -0.52% | 8.33% | 29.33% | -4.89% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 46.20% | -84.07% | 64.05% | -220.30% | 252.48% |
Change in Net Operating Assets | 431.06% | -88.03% | 31.97% | -426.84% | 29.28% |
Cash from Operations | 58.60% | 37.81% | 49.93% | -45.32% | -3.47% |
Capital Expenditure | -1,042.42% | 86.56% | 5.06% | -93.55% | -842.86% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -- | -- | -- | -- | -- |
Cash from Investing | -981.82% | 86.56% | 84.80% | -100.00% | 10.81% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -222.73% | 13.64% | 0.00% | 0.00% | 0.00% |
Issuance of Common Stock | -91.14% | 3,444.71% | 20,775.00% | 22,443.75% | 6,196.00% |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | 100.00% | -100.00% | -- | -- |
Cash from Financing | 209.92% | 6,862.79% | -85.53% | 305.95% | -60.58% |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | 157.32% | 70.93% | -129.71% | 536.99% | -194.94% |